Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024 – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...
2024-06-18 13:18:09 ET More on Celldex Celldex Therapeutics: Rising High, With Room For Further Growth Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celld...
2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...
2024-06-18 10:15:24 ET More on Roche Holding Roche Is Joining The Obesity Party But Questions Remain Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race Roche: Targeting Mega-Money Obesity Markets After Sharing Stunning Weight Loss Data ...
Roche receives FDA clearance on its digital pathology solution for diagnostic use PR Newswire The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling patho...
2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a muc...
2024-06-14 13:26:47 ET Summary Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP a...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
Roche receives FDA clearance on its digital pathology solution for diagnostic use PR Newswire The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling patho...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a muc...